CD20, IHC with Interpretation
Use
Immunohistochemical (IHC) staining for CD20 is used to evaluate B‑cell lineage in lymphoid tissues and neoplasms. CD20 antigen is expressed on most mature B lymphocytes and B‑cell lymphomas, and its detection supports diagnosis and classification of B‑cell proliferations. Interpretation by a pathologist helps assess presence, distribution, and intensity of staining, aiding in diagnostic and prognostic evaluation.
Special Instructions
Requires submission of appropriately prepared tissue specimens; CD20 IHC involves both the staining procedure and expert interpretive evaluation. Often used adjunctively in lymphoma panels. No additional special workflows noted.
Limitations
Limited by specimen adequacy, fixation, and preparation quality. False negatives may occur if antigen preservation is poor (e.g., over‑fixation, delayed fixation), and false positives may arise from non‑specific staining. Interpretation may be subjective and depends on pathologist expertise and antibody clone performance.
Methodology
Immunoassay (IHC)
Biomarkers
Result Turnaround Time
1-2 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Submit FFPE tissue block or cell block; if blocks unavailable, provide 1–2 unstained slides per antibody, 4 microns thick.
Storage Instructions
Ambient indefinite stability
Causes for Rejection
Slides or blocks with no tissue remaining; samples fixed in fixatives other than 10% neutral buffered formalin; overheated or frozen blocks.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Indefinite |